AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

AstraZeneca has spent $2 billion to strategically acquire a stake in Summit Therapeutics, pushing ivonescimab to the core stage of global tumor immunotherapy competition. This deal is not only a strong endorsement of the potential of this innovative Chinese drug, but also, at a time when Akeso Biopharma's latest OS data has attracted wide attention from the industry, further strengthens market expectations that ivonescimab could challenge the position of "K drug".

On September 29, according to Reuters, AstraZeneca will purchase Summit preferred shares at an equivalent price of $18.36 per ordinary share, a premium of 18.6% over Summit's Monday closing price of $15.48. The transaction is expected to be completed within this week. After the announcement, Summit's share price surged more than 18% after hours. The two parties also announced that they will jointly launch a series of clinical trials to test the combination of ivonescimab and AstraZeneca's cancer therapies, and have signed a preliminary agreement to explore combinations of ivonescimab with several AstraZeneca antibody-drug conjugates (ADCs).

The core asset of this deal is ivonescimab, developed by Akeso Biopharma and licensed to Summit in 2022 with a potential total consideration of up to $5 billion—the world's first PD-1/VEGF bispecific antibody. Analysts believe that AstraZeneca's involvement comes at a time window just after the release of key overall survival (OS) data for ivonescimab, which again outperformed Merck's "K drug" in a head-to-head trial, sending a strong market signal.

AstraZeneca Bets Big, Ivonescimab Wins Top Pharma Endorsement

According to reports, AstraZeneca’s $2 billion investment is a direct statement of confidence in ivonescimab as a potential next-generation cornerstone immunotherapy for cancer.

The mechanism of action of ivonescimab is to simultaneously block both the PD-1 and VEGF pathways—the former helps cancer cells evade immune detection, while the latter provides vascular support for tumor growth. Through the dual blockade, ivonescimab aims to enhance the immune system’s ability to recognize and attack cancer cells, offering a potential mechanistic advantage over single-target PD-1 inhibitors.

As part of the collaboration, AstraZeneca and Summit will jointly initiate clinical trials to test combination regimens of ivonescimab with AstraZeneca’s cancer therapies. The two sides have also signed a preliminary agreement to explore the combination potential of ivonescimab with multiple AstraZeneca ADC drugs—ADCs are a novel therapy capable of delivering cytotoxic drugs precisely to tumor cells and are currently a hot track in global cancer drug R&D.

This deal deeply binds AstraZeneca's R&D pipeline with ivonescimab and means that Summit gains heavyweight support in both capital and resources, helping drive ivonescimab’s further development and commercialization in the US and European markets.

OS Data Surpasses "K Drug" Again, Key Validation of Ivonescimab’s Clinical Value

AstraZeneca’s investment echoes Akeso Biopharma’s recently released OS data for ivonescimab.

According to The Economic Observer, on September 15, Akeso Biopharma presented overall survival (OS) data from the HARMONi-2 clinical trial at the World Conference on Lung Cancer (WCLC). As of August 20, 2026, with a median follow-up of 36 months, ivonescimab had a median OS of 30.8 months, compared to 22.6 months for "K drug", reducing the risk of death by 27%. The results reached the pre-specified statistical significance and showed clear clinical benefit.

OS is regarded by the industry as the "gold standard" metric for cancer treatment. Previously, ivonescimab had already announced an advantage over "K drug" based on progression-free survival (PFS) data—median PFS of 11.14 months versus "K drug"’s 5.82 months—in May 2024. The publication of this OS data further consolidates ivonescimab’s clinical value.

The report noted that on-site expert Mariana Brandão from the Jules Bordet Institute in Belgium stated that the benefits appeared to be mainly driven by the PD-L1 high-expression subgroup, and, surprisingly, also by the squamous cell carcinoma population—typically with a poor prognosis, but showing clear benefit in this data set. She expressed excitement about the data but pointed out that ivonescimab has higher toxicity compared to "K drug", and that there is currently a lack of biomarkers to predict which patients are more suitable for ivonescimab, so she would not immediately change clinical practice.

Mariana Brandão emphasized that the next key milestone is the global phase III HARMONi-7 trial specifically designed for the PD-L1 high-expression population, and its results will be decisive in showing whether ivonescimab can truly change clinical practice.

FDA Review Imminent, Overseas Commercial Prospects Still Uncertain

Ivonescimab’s internationalization process is at a critical juncture but uncertainties remain.

According to The Economic Observer, ivonescimab’s marketing application has been accepted by the US FDA as of January 2026, based on the global multicenter phase III HARMONi trial. The FDA is expected to make a review decision by November 14, 2026.

However, the HARMONi trial data did not perform as strongly as that of HARMONi-2. In May 2025, Summit disclosed that the primary OS analysis of ivonescimab combined with chemotherapy in the HARMONi study did not reach statistical significance; follow-up data showed some OS hazard ratio improvement, but results achieving statistical significance have not been disclosed so far.

At this year’s WCLC, Summit updated the HARMONi data, stating that among Western patient populations, with longer follow-up, patients in the ivonescimab arm continued to improve, indicating cross-regional consistency, but the persuasiveness of the full data set remains to be observed.

For Akeso Biopharma, overseas approval of ivonescimab is central to generating excess returns. In the first half of 2026, Akeso Biopharma achieved revenue of approximately 1.8 billion RMB, a year-on-year increase of 27.92%, mainly driven by domestic sales of ivonescimab and cadonilimab as its two core products.

Analysts believe that breakthroughs in overseas markets will still depend on the outcome of the FDA review, the progress of overseas clinical development, and the competitive landscape in the same therapeutic area.

"K Drug" Position Challenged, Next Generation Immunotherapy Layout Undecided

The rise of ivonescimab directly targets the market position of Merck’s "K drug" (pembrolizumab).

"K drug" is currently the cornerstone of cancer immunotherapy and has remained the world’s top-selling drug from 2023 to 2024, with sales expected to reach $31.68 billion in 2025. Akeso Biopharma positions ivonescimab as the next-generation cornerstone immunotherapy following "K drug".

Ivonescimab is the world’s first drug to surpass "K drug" in both PFS and OS endpoints in head-to-head clinical trials, a record that keeps the industry and investors highly focused. AstraZeneca’s $2 billion investment further brings this competition into the spotlight.

However, moving from clinical data to regulatory approvals and then to large-scale commercialization, ivonescimab still faces multiple challenges: the HARMONi global trial OS data has not yet reached statistical significance, efficacy data from Western patient populations still needs to be accumulated, and toxicity management and the development of patient screening tools also require time.

AstraZeneca’s participation provides strong endorsement for the global reach of ivonescimab, but whether it can ultimately shake the market position of "K drug" still awaits the FDA review result in November 2026.